SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

Sponsor
Vista Klinik
Study ID
NCT03409250
Phase
PHASE4
Status
Completed

Conditions

  • Age Related Macular Degeneration
  • Choroidal Neovascularization

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

This investigator initiated pilot study is designed to investigate the efficacy and safety of SD-OCT-guided intravitreal ranibizumab treatment in choroidal neovascularization (CNV) due to myopia. Newly diagnosed and active CNVs due to myopia are treated with one intravitreal injection of Ranibizumab 0.5mg (Lucentis) at baseline. During the follow up period of 12 months monthly ophthalmological examinations including best corrected visual acuity (BCVA) and high resolution spectral-domain optical coherence tomography (SD-OCT) assessments are performed. Detection of persisting or new signs of CNV activity at OCT triggers ranibizumab re-treatment considering that any ranibizumab injections can maximally be applied as often as monthly.

Key Dates

First listed
Jan 24, 2018
Start date
Jun 30, 2011
Status verified
Jan 2018
Primary completion
Jul 31, 2014
Completion
Jul 31, 2014

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: 1-Arm study
    prospective, 1-arm, monocenter, investigator initiated study Intravitreal injection with Lucentis (Ranibizumab)

Primary Outcome Measure

BCVA [ Time Frame: Baseline to 12-months ]

Related Studies